NCT02711228 - Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

January 30, 2018

Study Completion Date

January 30, 2018

Conditions

Primary Immune DeficiencySecondary Immune Deficiency

Interventions

BIOLOGICAL

Subcutaneous Immune Globulin (Human) (Hizentra)

Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.

Trial Locations (2)

QC H2W 1T7

Centre Hospitalier de l'université de Montréal, Montreal

QC H3T 1C4

CHU Sainte-Justine, Montreal